Clazakizumab and siltuximab directly target the site I of IL-6 for interfering the formation of IL-6 and IL-6R complex, and have been approved for the effectiveness in the treatment of rheumatoid arthritis (RA) and Castleman’s disease in clinical trials [81, 82]. This evidence concerns the gene IL6 and rheumatoid arthritis.